Monthly News Roundup - January 2025

FDA Clears Oral Journavx, a First-in-Class, Non-Opioid Pain Treatment from Vertex Pharmaceuticals On January 30th the FDA approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class, non-opioid analgesic to treat moderate to severe...

Articles similaires

FDA Approves Omlyclo (omalizumab-igec), an Interchangeable Biosimilar to Xolair

drugs.com - 07/Mar 22:03

March 07, 2025 -- Today, the U.S. Food and Drug Administration approved as the first interchangeable biosimilar to Xolair (omalizumab). Omlyclo, like...

Protega Pharmaceuticals collaborates with Wellgistics Health to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™

healthtechzone.com - 03/Mar 13:30

Monthly News Roundup - February 2025

drugs.com - 28/Feb 20:02

FDA Updates Izervay Label to Lengthen Treatment Duration for Geographic Atrophy Izervay (avacincaptad pegol) from Astellas is now FDA-approved without...

Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

drugs.com - 06/Mar 21:03

MONMOUTH JUNCTION, NJ, March 6, 2025 – Business Wire – Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company, today...

BBC opioid exposé: FDA suspends Aveo Pharmaceuticals’ GMP certificate

pulse.com.gh - 26/Feb 10:53

BBC opioid exposé: FDA suspends Aveo Pharmaceuticals’ GMP certificate

US FDA grants fast track designation to Latigo Biotherapeutics' LTG─001, an oral, investigational selective Nav1.8 inhibitor for the treatment of acute pain

pharmabiz.com - 04/Mar 23:54

Latigo Biotherapeutics (Latigo), a private clinical─stage biotechnology company, announced the US Food and Drug Administration (FDA) has granted...

Les derniers communiqués

Adobe Brings Conversational AI to Trillions of PDFs with the New AI Assistant in Reader and Acrobat
Adobe - 21/02/2024
Laura Frigenti takes the Helm as Chief Executive Officer of the Global Partnership for Education
Global Partnership for Education - 05/12/2022

Rubriques :

Monthly News Roundup - January 2025

Articles similaires

FDA Approves Omlyclo (omalizumab-igec), an Interchangeable Biosimilar to Xolair

Protega Pharmaceuticals collaborates with Wellgistics Health to support pharmacist education and increase patient access to the first and only FDA-approved abuse-deterrent immediate-release opioid, ROXYBOND™

Monthly News Roundup - February 2025

Tris Pharma Announces Positive Results from ALLEVIATE-2 Phase 3 Pivotal Trial for Cebranopadol, an Investigational First-in-Class Oral Dual-NMR Agonist, for the Treatment of Moderate-to-Severe Acute Pain

BBC opioid exposé: FDA suspends Aveo Pharmaceuticals’ GMP certificate

US FDA grants fast track designation to Latigo Biotherapeutics' LTG─001, an oral, investigational selective Nav1.8 inhibitor for the treatment of acute pain

FDA Approves Odactra for the Treatment of House Dust Mite Allergy in Young Children

Spark Biomedical Receives Health Canada’s Medical Device License for Sparrow Ascent Opioid Withdrawal Treatment

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

Scientists discover simple procedure to ease post-amputation pain

Les derniers communiqués